Scholarlink

Background <p>The pathogenesis of osteoarthritis (OA) is not yet fully elucidated. FABP4 plays a role in the occurrence of metabolic OA, however, the mechanism remains unclear. The purpose of this study was to further explore the mechanism by which FABP4 mediates the occurrence of metabolic OA.</p> Methods <p>In vivo, FABP4 knockout mice (KO) and wild-type littermates (WT) were fed with high-fat diet (HFD) for 3 and 6&#xa0;months. WT mice were fed with HFD and treated with FABP4 inhibitor BMS309403 (30&#xa0;mg/kg/d) or vehicle for 6&#xa0;months. Knee cartilage degenerative changes and subchondral bone changes were assessed. In vitro, FABP4 was used to stimulate mouse bone marrow mesenchymal stem cells (mMSCs) and endothelial progenitor cells (EPCs). Osteogenesis and angiogenesis were assessed.</p> Results <p>In vivo, knocking out of FABP4 and pharmaceutical inhibition of FABP4 significantly alleviated subchondral bone sclerosis and type H vessel formation in mice fed with HFD, and was significantly associated with osteogenesis and angiogenesis. In vitro, FABP4 promotes the differentiation of MSCs into osteoblasts through activation of the PI3K/Akt signaling pathway, and promotes the expression of osteogenesis-related proteins. FABP4 also promotes endothelial cell migration, tube formation, and wound healing through activating the PI3K/Akt pathway.</p> Conclusions <p>This study suggests that FABP4 induced subchondral bone osteogenesis and angiogenesis. The PI3K-Akt signaling pathway plays a critical role in both processes. Inhibition of FABP4 may serve as a potential therapeutic approach for metabolic OA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fatty acid binding protein 4 induces osteogenesis and angiogenesis as pathogenesis of metabolic osteoarthritis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月19日

查看全文
  • Chaofan Zhang,
  • Yinjun Mao,
  • Yishan Xin,
  • Hongyan Li,
  • Maocan Cai,
  • Yiming Lin,
  • Xuehui Zhang,
  • Ying Huang,
  • Yang Chen,
  • Zida Huang,
  • Xinyu Fang,
  • Wenming Zhang,
  • Yunzhi Lin

摘要

Background

The pathogenesis of osteoarthritis (OA) is not yet fully elucidated. FABP4 plays a role in the occurrence of metabolic OA, however, the mechanism remains unclear. The purpose of this study was to further explore the mechanism by which FABP4 mediates the occurrence of metabolic OA.

Methods

In vivo, FABP4 knockout mice (KO) and wild-type littermates (WT) were fed with high-fat diet (HFD) for 3 and 6 months. WT mice were fed with HFD and treated with FABP4 inhibitor BMS309403 (30 mg/kg/d) or vehicle for 6 months. Knee cartilage degenerative changes and subchondral bone changes were assessed. In vitro, FABP4 was used to stimulate mouse bone marrow mesenchymal stem cells (mMSCs) and endothelial progenitor cells (EPCs). Osteogenesis and angiogenesis were assessed.

Results

In vivo, knocking out of FABP4 and pharmaceutical inhibition of FABP4 significantly alleviated subchondral bone sclerosis and type H vessel formation in mice fed with HFD, and was significantly associated with osteogenesis and angiogenesis. In vitro, FABP4 promotes the differentiation of MSCs into osteoblasts through activation of the PI3K/Akt signaling pathway, and promotes the expression of osteogenesis-related proteins. FABP4 also promotes endothelial cell migration, tube formation, and wound healing through activating the PI3K/Akt pathway.

Conclusions

This study suggests that FABP4 induced subchondral bone osteogenesis and angiogenesis. The PI3K-Akt signaling pathway plays a critical role in both processes. Inhibition of FABP4 may serve as a potential therapeutic approach for metabolic OA.